Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620001265965
Ethics application status
Not required
Date submitted
5/09/2020
Date registered
25/11/2020
Date last updated
25/11/2020
Date data sharing statement initially provided
25/11/2020
Date results information initially provided
25/11/2020
Type of registration
Retrospectively registered
Titles & IDs
Public title
Epidemiology and clinical features in patients with COVID-19 in Mexican Southeast: A retrospective analysis
Query!
Scientific title
Epidemiology and clinical features in patients with COVID-19 in Mexican Southeast: A retrospective analysis
Query!
Secondary ID [1]
301931
0
None
Query!
Universal Trial Number (UTN)
None
Query!
Trial acronym
None
Query!
Linked study record
None
Query!
Health condition
Health condition(s) or problem(s) studied:
COVID-19
318453
0
Query!
Condition category
Condition code
Infection
316461
316461
0
0
Query!
Studies of infection and infectious agents
Query!
Respiratory
316462
316462
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Coronavirus disease 2019 (COVID-19) caused by the virus SARS-CoV-2 defines as a pandemic respiratory infection that causes fever, cough, dyspnea, and pulmonary interstitial damage. Unfortunately, SARS-CoV-2 is fastly transmittable between humans and has affected approximately 17.6 million people worldwide. As of July 2020, the World Health Organization (WHO) reported around 425000 confirmed cases in Mexico. In Tabasco, a state of the southeast of Mexico has reported 21300 cases for COVID-19.
The "Dr. Juan Graham Casasús" Hospital received nearly 3000 patients during the pick of the pandemic. Therefore, this proposal is based on the outcomes of hospitalized patients by COVID-19 in Tabasco. This retrospective study will evaluate the medical records of patients diagnosed with COVID-19 in a third-level hospital in Tabasco, from admission until discharge/death.
We will collect sociodemographic, comorbidities, and clinical symptoms at admission, then pharmacological treatment, and laboratory data.
Query!
Intervention code [1]
318216
0
Not applicable
Query!
Comparator / control treatment
No control group.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
325008
0
Gender and age with high mortality by COVID-19 in "Dr. Juan Graham Casasús" Hospital in Tabasco Mexico.
Query!
Assessment method [1]
325008
0
Query!
Timepoint [1]
325008
0
Hospital admission until discharge or death through clinical records.
Query!
Primary outcome [2]
325023
0
Routine blood test (complete blood count, coagulation test), in patients hospitalized by COVID-19.
Query!
Assessment method [2]
325023
0
Query!
Timepoint [2]
325023
0
Routine blood test were performed at hospital admission (baseline) and will include three timepoints until discharge or death. We obtained complete blood count, coagulation test, and inflammatory markers through clinical records.
Query!
Primary outcome [3]
325529
0
Inflammatory markers (PCR, IL-6, Ferritin) in patients hospitalized by COVID-19.
Query!
Assessment method [3]
325529
0
Query!
Timepoint [3]
325529
0
Inflammatory markers were performed at hospital admission (baseline) and will include three timepoints until discharge or death. We obtained complete blood count, coagulation test, and inflammatory markers through clinical records.
Query!
Secondary outcome [1]
386538
0
Presence hypertension in patients with COVID-19 in "Dr. Juan Graham Casasús" Hospital in Tabasco Mexico.
Query!
Assessment method [1]
386538
0
Query!
Timepoint [1]
386538
0
Hospital admission through clinical records.
Query!
Secondary outcome [2]
389064
0
Presence of diabetes in patients with COVID-19 in "Dr. Juan Graham Casasús" Hospital in Tabasco Mexico.
Query!
Assessment method [2]
389064
0
Query!
Timepoint [2]
389064
0
Hospital admission through clinical records.
Query!
Secondary outcome [3]
389065
0
Presence of obesity in patients with COVID-19 in "Dr. Juan Graham Casasús" Hospital in Tabasco Mexico.
Query!
Assessment method [3]
389065
0
Query!
Timepoint [3]
389065
0
Hospital admission through clinical records.
Query!
Eligibility
Key inclusion criteria
All survivors and non-survivors patients diagnosed with COVID-19 in a third level hospital in Tabasco, Mexico.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients hospitalized by other clinical conditions.
Patients without vital signs at respiratory triage.
Patients hospitalized with incomplete clinical records.
Pregnancy women.
Age <18 years.
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Both
Query!
Statistical methods / analysis
First, all data will be analyzed by the descriptive statistic.
To describe demographic, clinical, and laboratory variables will be used a frequency distribution, central tendency, and dispersion, according to the case.
Second, we will compare all variables in survivor and non-survivor patients. Categorical variables will compare using the x2 test or Fisher’s test., Quantitative variables will be compared using the t-test.
Third, multiple logistic regression will be used to identify predictors of mortality.
All analyses will be processed by SPSS for windows version 21.0.
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/03/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
15/09/2020
Query!
Date of last data collection
Anticipated
31/12/2020
Query!
Actual
Query!
Sample size
Target
1000
Query!
Accrual to date
Query!
Final
1000
Query!
Recruitment outside Australia
Country [1]
22918
0
Mexico
Query!
State/province [1]
22918
0
Tabasco
Query!
Funding & Sponsors
Funding source category [1]
306345
0
Hospital
Query!
Name [1]
306345
0
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasús"
Query!
Address [1]
306345
0
Calle Uno S/N, Miguel Hidalgo III Etapa, 86126 Villahermosa, Tab., México.
Query!
Country [1]
306345
0
Mexico
Query!
Primary sponsor type
Hospital
Query!
Name
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasús"
Query!
Address
Calle Uno S/N, Miguel Hidalgo III Etapa, 86126 Villahermosa, Tab., México.
Query!
Country
Mexico
Query!
Secondary sponsor category [1]
306849
0
None
Query!
Name [1]
306849
0
Query!
Address [1]
306849
0
Query!
Country [1]
306849
0
Query!
Ethics approval
Ethics application status
Not required
Query!
Summary
Brief summary
SARS-CoV-2 is fastly transmittable between humans and has affected approximately 17.6 million people worldwide. As of July 2020, the World Health Organization (WHO) reported around 425000 confirmed cases in Mexico.
In Tabasco, a state located in southeast Mexico reported 21300 cases for COVID-19. It is noteworthy that "Dr. Juan Graham Casasús" Hospital is the most important for the COVID-19 attention in Tabasco. Hence, the present study aims to determine the sociodemographic, clinical, imaging features, and biochemical levels of adult survivors and non-survivors of COVID-19 infection treated at the "Dr. Juan Graham Casasus" Hospital in Tabasco, Mexico.
So the retrospective analysis of the epidemiology and clinical features in patients with COVID-19 contributes to the scientific actualization of clinical work carried out during the pandemic.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Ethics approval is not required for this study because this work is categorizing as risk-free in Mexico. Due to this, retrospective nature will be obtained data from the medical records and will be guaranteed the anonymity of the patients.
Query!
Contacts
Principal investigator
Name
104270
0
Dr Jesús Arturo Ruiz Quiñones
Query!
Address
104270
0
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus".
Calle Uno S/N, Miguel Hidalgo III Etapa, 86126 Villahermosa, Tabasco, México.
Query!
Country
104270
0
Mexico
Query!
Phone
104270
0
+529933100300
Query!
Fax
104270
0
Query!
Email
104270
0
[email protected]
Query!
Contact person for public queries
Name
104271
0
Dr Jesús Arturo Ruiz Quiñones
Query!
Address
104271
0
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus".
Calle Uno S/N, Miguel Hidalgo III Etapa, 86126 Villahermosa, Tabasco, México.
Query!
Country
104271
0
Mexico
Query!
Phone
104271
0
+529933100300
Query!
Fax
104271
0
Query!
Email
104271
0
[email protected]
Query!
Contact person for scientific queries
Name
104272
0
Dr Guadalupe del Carmen Baeza Flores
Query!
Address
104272
0
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus".
Calle Uno S/N, Miguel Hidalgo III Etapa, 86126 Villahermosa, Tabasco, México.
Query!
Country
104272
0
Mexico
Query!
Phone
104272
0
+529933100300
Query!
Fax
104272
0
Query!
Email
104272
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Plain language summary
No
None
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Clinical and Virological Features of SARS-CoV-2 Variants during the Four Waves of the Pandemic in the Mexican Southeast
2023
https://doi.org/10.3390/tropicalmed8030134
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF